ReviewJournal of cardiovascular translational research2013
New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy.
Review in Journal of cardiovascular translational research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Development and Evaluation of a Clinical Prediction Model for Acute Kidney Injury Risk in Elderly Patients with Heart Failure with Reduced Ejection Fraction.Global heart · 2026Article
- Dynamic LVEF Decline and Serum NT-proBNP and Uric Acid Levels before Heart Transplantation are Independent Predictors of Adverse Outcomes in Young Adult Patients with Dilated Cardiomyopathy.Reviews in cardiovascular medicine · 2024Article
- A pilot study of S100A4, S100A8/A9, and S100A12 in dilated cardiomyopathy: novel biomarkers for diagnosis or prognosis?ESC heart failure · 2024Article
- Peri-event plasma PCSK9 and hsCRP after an acute myocardial infarction correlate with early deterioration of left ventricular ejection fraction: a cohort study.Lipids in health and disease · 2022Article
- Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy.International journal of molecular sciences · 2021Review
- H2S improves doxorubicin-induced myocardial fibrosis by inhibiting oxidative stress and apoptosis via Keap1-Nrf2.Technology and health care : official journal of the European Society for Engineering and Medicine · 2021Article
- The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy.Frontiers in cardiovascular medicine · 2021Review
- Cardiac Metabolic Limitations Contribute to Diminished Performance of the Heart in Aging.Biophysical journal · 2019Article
- Examination of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) as a Potential Biomarker in Heart Failure Patients.Journal of molecular neuroscience : MN · 2019Article
- Proteomic signature of circulating extracellular vesicles in dilated cardiomyopathy.Laboratory investigation; a journal of technical methods and pathology · 2018Article
- Omega-3 polyunsaturated fatty acids prevent murine dilated cardiomyopathy by reducing oxidative stress and cardiomyocyte apoptosis.Experimental and therapeutic medicine · 2017Article
- Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy.Journal of cellular and molecular medicine · 2017Article
- Traditional Chinese medicine baoxin decoction improves cardiac fibrosis of rats with dilated cardiomyopathy.Experimental and therapeutic medicine · 2017Article
- Influence of metabolic dysfunction on cardiac mechanics in decompensated hypertrophy and heart failure.Journal of molecular and cellular cardiology · 2016Article
- Circulating Endothelial Progenitor Cells: Potential Biomarkers for Idiopathic Dilated Cardiomyopathy.Journal of cardiovascular translational research · 2016Article
- S-Nitrosylation Proteome Profile of Peripheral Blood Mononuclear Cells in Human Heart Failure.International journal of proteomics · 2016Article
- Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease.Journal of cardiovascular translational research · 2015Article
- Molecular mechanisms behind progressing chronic inflammatory dilated cardiomyopathy.BMC cardiovascular disorders · 2015Article
- Recurrence of left ventricular dysfunction in patients with restored idiopathic dilated cardiomyopathy.Clinical cardiology · 2014Article
- Biomarkers and heart disease: what is translational success?Journal of cardiovascular translational research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Dilated cardiomyopathy (DCM) is characterized by deteriorating cardiac performance, impaired contraction and dilation of the left ventricle (or both ventricles). Blood markers--known as "biomarkers"--allow insight into underlying pathophysiologic mechanisms and biologic pathways while predicting outcomes and guiding heart failure management and/or therapies. In this review, we provide an alternative approach to conceptualize heart failure biomarkers: the cardiomyocyte, its surrounding microenvironment, and the macroenvironment, integrating these entities which may impact cellular processes involved in the pathogenesis and/or propagation of DCM. Newer biomarkers of left ventricular systolic dysfunction can be categorized under: (a) myocyte stress and stretch, (b) myocyte apoptosis, (c) cardiac interstitium, (d) inflammation, (e) oxidative stress, (f) cardiac energetics, (g) neurohormones, and (h) renal biomarkers. Biomarkers provide insight into the pathogenesis of DCM while predicting and potentially providing prognostic information in these patients with heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.